secwatch.observer — SEC 8-K summary
======================================

Issuer:     KYNTRA BIO, INC. (KYNB)
CIK:        0000921299
Form:       8-K
Filed at:   2025-05-12T23:59:59+00:00
Accession:  0000950170-25-069159
Event type: earnings
Sentiment:  neutral
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

FibroGen Q1 net loss narrows to $16.8M; China sale consideration raised to ~$185M
--------------------------------------------------------------------------------

- Total revenue from continuing ops fell to $2.7M from $25.4M YoY; net loss improved to $16.8M ($0.16/sh) from $49.0M.
- Sale of FibroGen China to AstraZeneca now expected total consideration ~$185M (enterprise $85M + net cash ~$100M); close in 3Q-2025.
- Upon China sale close, cash runway extended into 2H 2027; Morgan Stanley term loan to be repaid.
- Phase 2 monotherapy trial of FG-3246 (CD46 ADC) in mCRPC expected to start 3Q-2025; topline combo data from UCSF study due 4Q-2025.
- Filed Type-C meeting request with FDA for roxadustat in LR-MDS anemia; feedback expected in 3Q-2025.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/921299/000095017025069159/0000950170-25-069159-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/921299/000095017025069159/fgen-20250512.htm
  HTML page:      https://secwatch.observer/filing/0000950170-25-069159

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer